Decision Resources Research Reports

Title	Published	Price
Realizing the Promise of Therapeutic RNAi: Emerging Strategies for RNAi Delivery By: Decision Resources The discovery of RNA interference (RNAi) has renewed interest in developing nucleic acid drugs based on targeting messenger RNAs (mRNAs). This field of research offers the potential to produce low-dose, nontoxic RNAi agents to treat \| more...	1/31/2008	$1,125.00
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Fourth Quarter of 2007 By: Decision Resources The fourth quarter of 2007 was fairly quiet in the pricing and reimbursement arena. In the United States, the presidential election, legislation in California, and a new initiative from health plans focused attention on the \| more...	1/31/2008	$1,125.00
SPECIAL REPORT: State of the Pharmaceutical Industry, 2008 By: Decision Resources What will pharmaceutical management see when it looks in the mirror in 2008? Amid the pressures and shortcomings of recent industry performance, will management recognize and act upon the opportunities that already exist? Adhering to \| more...	1/24/2008	$2,250.00
HIV Vaccine Update: R&D Innovation Critical in the Wake of Recent Setbacks By: Decision Resources Despite 25 years of extensive research, an HIV vaccine remains an elusive target. More-innovative approaches to vaccine development are urgently needed. Although this high-risk, high-profile area of development is crucial to world health, it is \| more...	12/28/2007	$1,668.75
SPECIAL REPORT: Blockbusters Then and Now—Trends for Billion-Dollar Drugs By: Decision Resources Small-molecule pharmaceutical manufacturers have had a rough year: 2007 saw the abrupt ending of the development of many highly anticipated blockbuster compounds. Now, many small-molecule companies are left with an aging portfolio of blockbuster products \| more...	12/28/2007	$2,250.00
SPECIAL REPORT: 2007 Industry Dynamics - Lessons Learned By: Decision Resources Moderate successes and "business as usual" characterize the performance of the pharmaceutical industry in 2007. In this year-end retrospective report, we contemplate the importance of key events and achievements in the industry. We asked industry-leading \| more...	12/27/2007	$2,250.00
The Avastin Juggernaut: Transformation of the Age-Related Macular Degeneration Market By: Decision Resources The AMD market is witnessing an unusual scenario in which two agents from the same company are competing for the market-leading position. Although Genentech’s Lucentis is an effi cacious therapy approved for AMD, Genentech’s Avastin \| more...	12/19/2007	$1,668.75
R&D Update: How Can Companies Improve on Existing Antiangiogenesis Agents? By: Decision Resources Antiangiogenic drugs represent a new class of antitumor therapeutics that will be used along with cytotoxic agents, targeted agents, and immunomodulatory agents to fi ght cancer. The fi rst antiangiogenic compound on the market, Genentech’s \| more...	12/19/2007	$1,668.75
Beyond Disease Management: Strategies for Improving Patient Care and Cutting Costs By: Decision Resources Disease management has become a common term in the U.S. health care system. Yet, the more widely the term has been adopted, the more diffuse the defi nition of this health care strategy has become. \| more...	12/14/2007	$1,112.50
Pricing and Reimbursement of Next Generation Diagnostics in the United States By: Decision Resources Next-generation diagnostics promise to offer an enhanced ability to diagnose disease and to provide moretargeted drug therapy to patients. However, for manufacturers of these new technologies, navigating the current pricing and reimbursement structure of major \| more...	12/13/2007	$1,112.50
Success Principles: Making Pharmaceutical Business Development Fit for Purpose By: Decision Resources In today’s competitive and evolving pharmaceutical landscape, Business Development is a strategic lifeline for all companies. The more successful Business Development departments share factors that clearly distinguish them from the pack. These success principles can \| more...	12/13/2007	$1,112.50
Emerging Drug Targets in Alzheimer’s Disease By: Decision Resources The lack of effective treatments for Alzheimer’s disease (AD) and an aging population create an enormous opportunity for disease-modifying drugs. Competition to develop new drugs for AD is in fact fi erce, and the ef- \| more...	12/12/2007	$1,112.50
Preventing Cardiovascular Events: Will HDL Therapeutics Change the Treatment Paradigm? By: Decision Resources The notion that raising HDL cholesterol levels can reduce the risk of coronary heart disease is not a new one, yet drug developers have been continually foiled in their attempts to capitalize on this fi \| more...	12/12/2007	$1,668.75
Next-Generation Biologics: Improving on Monoclonal Antibodies By: Decision Resources Monoclonal antibodies (MAbs) have become the most successful platform for targeted biotherapeutics, demonstrating high affi nity and specifi city for their target and considerably lower toxicity than small-molecule drugs. Technological advances in the development and \| more...	12/12/2007	$1,668.75
Managed Care Industry in the United States: Healthy and Hungry for Continued Growth By: Decision Resources With commercial enrollment stalled, the managed care industry is looking for creative ways to grow business. Five years of profits have given health insurers the wherewithal to make deals and invest in new ventures. Mergers \| more...	12/11/2007	$1,112.50
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Third Quarter of 2007 By: Decision Resources The third quarter of 2007 was a quiet period in terms of legislation and other major developments in pricing and reimbursement in the major pharmaceutical markets, but recent trends in cost containment continued. In this \| more...	12/11/2007	$1,112.50
International Trends in the Use of Health Technology Assessment By: Decision Resources Health technology assessment (HTA)—which typically involves the use of cost-effectiveness studies to evaluate the relative value of a new drug or medical technology—can play a key role in helping reimbursement authorities determine which medical treatments \| more...	12/7/2007	$1,112.50
Licensing Strategies for Accessing Biomarker Technologies By: Decision Resources Biomarkers play an increasingly important role in drug discovery and development. A large number of companies have emerged that provide various biomarker-related tools and services. The various stakeholders in the biomarker industry—specifi cally, biopharmaceutical companies, \| more...	12/7/2007	$1,112.50
Influencing the Development of NICE Technology Appraisals and Guidelines: Lessons for the Pharmaceutical Industry By: Decision Resources The U.K. National Institute for Health and Clinical Excellence (NICE) is increasingly infl uencing the fateof drugs, other health care technologies, and general clinical practice in many countries. Pharmaceutical anddevice manufacturers will greatly benefi t \| more...	11/29/2007	$1,112.50
Outsourcing Drug Discovery to China and India By: Decision Resources Driven by the need to improve R&D productivity and effi ciency and the desire to access untapped markets,global pharmaceutical companies have increasingly offshored and outsourced operations to CROs in Chinaand India. A wide array of \| more...	11/27/2007	$1,112.50
Challenges and Opportunities in Developing Chemopreventive Agents By: Decision Resources During the past 30 years, researchers’ understanding of cancer progression has increased tremendously. This critical development has allowed for the possibility of developing cancer chemopreventive agents. Among potential chemopreventive agents, modalities that are already approved \| more...	11/27/2007	$1,668.75
Business Strategies for Different Types of Biogenerics By: Decision Resources The rush to develop and market biogenerics has begun. While the United States dragged its feet drafting legislationto codify issues surrounding biogenerics, biogenerics companies have successfully brought products to severalother markets around the world. Looking \| more...	11/27/2007	$1,112.50
Nicotinic Receptor Agonists for Treating Diseases of Cognitive Dysfunction By: Decision Resources Nicotine has long been known to improve cognitive function, but its adverse effects make it problematic as a treatment for diseases of cognitive dysfunction. Recent research has revealed that certain subtypes of nicotinic acetylcholinesterase receptors \| more...	11/13/2007	$1,668.75
SPECIAL REPORT: Dealmaking and Financing: Technology Partnering Opportunities By: Decision Resources Technology revolutions, convergence, and new paradigms of drug discovery and development─these are exciting times for the pharmaceutical industry. Technological innovation is fl ourishing and intense competition exists among companies that hope to license or acquire \| more...	11/8/2007	$1,112.50
Expanding Drug Markets: Pharmaceutical Companies' Role in Redefining Disease By: Decision Resources In the early 1990s, a new, not-so-fl attering term—disease mongering—emerged to describe pharmaceutical companies’ efforts to extend the boundaries of illness and create “new” disease markets. The ultimate example is erectile dysfunction (ED), a virtually \| more...	11/5/2007	$1,668.75
Title	Published	Price

< prev 1 2 3 4 5 6 7 8 9 10 next >

Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: customerservice@marketresearch.com
Copyright © 1999-2009, All Rights Reserved, MarketResearch.com
11/23/2009 - 2